Darbepoetin Alpha in the Treatment of Cancer Chemotherapy-Induced Anemia

Therapeutics and Clinical Risk Management - New Zealand
doi 10.2147/tcrm.2007.3.2.269
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

PCN38 Economic Evaluation of Darbepoetin Alpha in the Management of Patients With Chemotherapy Induced Anemia (CIA) in Greece

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Managing Chemotherapy Induced Anemia With Darbepoetin Alfa and Other Erythropoiesis Stimulating Agents: A Nurse's Perspective

Nursing: Research and Reviews
2013English

Darbepoetin Versus Epoetin Alfa for the Correction of Anemia in Cancer Patients Receiving Radiotherapy or Chemoradiotherapy Treatment

Clinical medicine. Oncology
2008English

Potential Health Economic Impact of Intravenous Iron Supplementation to Erythropoiesis-Stimulating Agent Treatment in Patients With Cancer- Or Chemotherapy-Induced Anemia

Oncology
MedicineCancer ResearchOncology
2011English

Suicidal Death of Erythrocytes in Cancer and Its Chemotherapy: A Potential Target in the Treatment of Tumor-Associated Anemia

International Journal of Cancer
Cancer ResearchOncology
2017English

Epidemiology of Chemotherapy-Induced Anemia in Patients With Non-Hodgkin Lymphoma

Permanente journal,The
Medicine
2019English

Neoadjuvant Chemotherapy in the Treatment of Cervical Cancer

2012English

PCN34 Cost Analysis of Anemia Treatment With Erythropoiesis-Stimulating Agents (ESAs) in Cancer Patients Receiving Chemotherapy in Italy

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Anemia Treatment With Q2W Darbepoetin Alfa in Patients With Chronic Kidney Disease Naïve to Erythropoiesis-Stimulating Agents

Current Medical Research and Opinion
Medicine
2008English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy